The Science
What is the Tesamorelin / Ipamorelin 10/5 Blend?
Tesamorelin is a stabilized GHRH analog (GHRH 1-44 with a trans-3-hexenoyl modification) developed for its visceral adipose tissue-reducing properties in HIV-associated lipodystrophy research.
Ipamorelin is a selective pentapeptide ghrelin receptor agonist that stimulates pulsatile GH release without significantly elevating cortisol, prolactin, or aldosterone.
The 10:5 ratio offers a more ghrelin-weighted co-stimulus than the 10:2 variant, producing a larger combined GH pulse in pituitary cell models while maintaining a clean hormonal profile.
Laboratory Observations
Key Observed Effects in Research
Greater GH Amplitude
Higher Ipamorelin loading produces larger combined GH pulses in laboratory assays.
VAT-Targeted Action
Tesamorelin component retains its visceral fat-reduction signature.
IGF-1 Pathway
Downstream hepatic IGF-1 production elevated in animal models.
Selective Hormonal Profile
Avoids cortisol and prolactin elevation.
Mechanism of Action
Balanced Dual-Pathway GH Stimulation
Sustained GHRH Activation
Tesamorelin engages GHRH receptors with extended plasma exposure relative to native GHRH.
Visceral Adipose Pathway
Tesamorelin's documented effect on VAT is preserved in the combination.
Pulsatile Preservation
Despite stabilized Tesamorelin pharmacokinetics, GH release remains pulsatile in published research.
Research-Only Notice
2X Blend Tesamorelin (10mg) / Ipamorelin (5mg) is categorized by the FDA as for research-purposes-only. It is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease. The information above summarizes effects observed in laboratory studies to date and is provided strictly for scientific and educational reference.